AKESOGEN, INC.

Akesogen, Inc. specializes in advanced genomic analysis services, delivering precision laboratory testing and data-driven biological insights primarily for federal health missions. Their core capabilities center on high-throughput sequencing, bioinformatics pipeline development, and clinical-grade genomic interpretation, with a demonstrated focus on translating complex genetic data into actionable intelligence for veteran healthcare applications. The company’s technical expertise includes variant calling, SNP and CNV analysis, transcriptomic profiling, and compliance with CLIA and CAP standards for diagnostic laboratories. Akesogen distinguishes itself through consistent execution in mission-critical genomic research environments, emphasizing reproducibility, data integrity, and regulatory alignment in sensitive health contexts. The Department of Veterans Affairs is the contractor’s primary and consistent partner, with multiple consecutive awards for genomic analysis services. This sustained engagement suggests a trusted, long-term relationship built on reliable delivery of specialized genetic testing and analysis to support veteran-specific health initiatives, including personalized medicine, chronic disease profiling, and military exposure-related biomarker research. Akesogen operates primarily within NAICS 541380, which encompasses clinical and research laboratory services focused on diagnostic testing and biological analysis. Their market positioning is narrowly defined by expertise in genomic diagnostics rather than broad laboratory services, placing them as a niche provider in the federal precision medicine space. They serve a specialized segment of the life sciences and veteran healthcare market where genetic data informs clinical decision-making. As a small business structured as a 2L entity based in Peachtree Corners, Georgia, Akesogen maintains a lean, focused operational model. While no federal certifications are listed, their repeated award history with the VA underscores their credibility in meeting stringent government standards for quality, security, and scientific rigor in genomic testing.